Every day, we strive to discover, develop and trial new ways to enhance patient comfort, improve treatment outcomes and help patients live better and healthier lives.
Survival rates are our why. It’s why we’ve created innovation to end the need for painful, repeat biopsies. It’s why we’ve developed our market leading CD8 ImmunoPET imaging agent that provides full body scans; And it’s why we created RPT, to accelerate the healing process through advanced radiation therapy technology.
It’s also why, in the future, we’ll continue to add to our range of radiopharmaceutical products to meet more unique medical needs and continue to merge biotech and pharmaceutical innovations for greater clarity and comfort.
Read on to discover more about RPT, our theranostic solution based on our minibody and cys-diabodies platform technologies.
RPT uses targeted radiation to kill cancer. Our platform technologies is the ideal platform to generate best in indication RPT treatment because they achieve:
By taking the middle ground between the size of a small molecule/peptide and an antibody, our treatment has a longer time in blood-pool to distribute the drug into cancer tissues and is able to penetrate further into tumors than larger long-circulating antibodies.
Compared to small molecules and peptides, our minibodies and cys-diabodies reduce off target radiation dose related toxicities.
As biologicals. minibodies and cys-diabodies have highly selective tumor binding and are internalized, ensure payload delivery to target tissue, characteristic not found with many small molecules and peptides
We believe minibodies and cys dibodies are “the Goldilocks technology of RPT” with the ideal binding affinity, ideal tumor uptake and ideal clearance from the body
In just 4-6 months, we’re able to achieve from ideal to lead binder.
The binder progresses to lead product. We add a therapeutic isotope, and validate the product in pre-clinical models. This enables us to see how the agent reduces tumor growth and whether the distribution of the agent is high in tumors and has the right in vivo characteristics.
Safety studies are carried out alongside a clinical grade manufacture, to enable us to undertake a clinical study. This takes approximately 1 year.
Ian's diverse portfolio of skills, along with his aspirational vision of growing ImaginAb to transform the healthcare and biotechnology industry has led Mr. Wilson to accelerate ImaginAb’s business presence and performance.
Alessandro is hugely passionate about his field and realizes that cancer affects almost everyone at some point of their lives. He hopes his participation in research will contribute to enhancing people’s lives and improving their life expectancy.
Overseeing ImaginAb's operational functions including Project Management, CMC, Quality, Regulatory, Pharmacovigilance and Clinical Operations, William has over 17 years of experience in drug development in the CRO, pharmaceutical and biotechnology industry.
Gareth has over 15 years’ experience in the field of nuclear medicine diagnostics and radiopharmaceutical therapies. Owing to his passion for the continuous improvement of patient care Gareth remains in touch with several spin-outs he has worked with to support thinking on commercialisation of new concepts.